메뉴 건너뛰기




Volumn 79, Issue 6, 2016, Pages 950-958

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; NATALIZUMAB; RITUXIMAB; VIRUS ANTIBODY; ANTIBODY;

EID: 84963961057     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24651     Document Type: Article
Times cited : (194)

References (25)
  • 1
    • 84913555304 scopus 로고    scopus 로고
    • Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
    • Plavina T, Subramanyam M, Bloomgren G, et al., Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 802-812.
    • (2014) Ann Neurol , vol.76 , pp. 802-812
    • Plavina, T.1    Subramanyam, M.2    Bloomgren, G.3
  • 2
    • 84861022041 scopus 로고    scopus 로고
    • Risk of natalizumab-associated progressive multifocal leukoencephalopathy
    • Bloomgren G, Richman S, Hotermans C, et al., Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
    • (2012) N Engl J Med , vol.366 , pp. 1870-1880
    • Bloomgren, G.1    Richman, S.2    Hotermans, C.3
  • 3
    • 84904748984 scopus 로고    scopus 로고
    • Natalizumab: Risk stratification of individual patients with multiple sclerosis
    • Tur C, Montalban X,. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs 2014; 28: 641-648.
    • (2014) CNS Drugs , vol.28 , pp. 641-648
    • Tur, C.1    Montalban, X.2
  • 4
    • 77956387401 scopus 로고    scopus 로고
    • Anti-JC virus antibodies: Implications for PML risk stratification
    • Gorelik L, Lerner M, Bixler S, et al., Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
    • (2010) Ann Neurol , vol.68 , pp. 295-303
    • Gorelik, L.1    Lerner, M.2    Bixler, S.3
  • 5
    • 79960344014 scopus 로고    scopus 로고
    • Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring
    • Kappos L, Bates D, Edan G, et al., Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-758.
    • (2011) Lancet Neurol , vol.10 , pp. 745-758
    • Kappos, L.1    Bates, D.2    Edan, G.3
  • 6
    • 79958137883 scopus 로고    scopus 로고
    • Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
    • O'Connor PW, Goodman A, Kappos L, et al., Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865.
    • (2011) Neurology , vol.76 , pp. 1858-1865
    • O'Connor, P.W.1    Goodman, A.2    Kappos, L.3
  • 7
    • 77956388036 scopus 로고    scopus 로고
    • Natalizumab dosage suspension: Are we helping or hurting?
    • West TW, Cree BA,. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395-399.
    • (2010) Ann Neurol , vol.68 , pp. 395-399
    • West, T.W.1    Cree, B.A.2
  • 8
    • 84902548597 scopus 로고    scopus 로고
    • Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients
    • Sangalli F, Moiola L, Ferre L, et al., Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Mult Scler Relat Disord 2014; 3: 520-526.
    • (2014) Mult Scler Relat Disord , vol.3 , pp. 520-526
    • Sangalli, F.1    Moiola, L.2    Ferre, L.3
  • 9
    • 79951543155 scopus 로고    scopus 로고
    • Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy
    • Miravalle A, Jensen R, Kinkel RP,. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186-191.
    • (2011) Arch Neurol , vol.68 , pp. 186-191
    • Miravalle, A.1    Jensen, R.2    Kinkel, R.P.3
  • 10
    • 84905968845 scopus 로고    scopus 로고
    • Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: Evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)
    • Clerico M, Schiavetti I, De Mercanti SF, et al., Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol 2014; 71: 954-960.
    • (2014) JAMA Neurol , vol.71 , pp. 954-960
    • Clerico, M.1    Schiavetti, I.2    De Mercanti, S.F.3
  • 11
    • 84893060675 scopus 로고    scopus 로고
    • We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?
    • Fragoso YD, Arruda NM, Arruda WO, et al., We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it? Expert Rev Neurother 2014; 14: 127-130.
    • (2014) Expert Rev Neurother , vol.14 , pp. 127-130
    • Fragoso, Y.D.1    Arruda, N.M.2    Arruda, W.O.3
  • 12
    • 84947790954 scopus 로고    scopus 로고
    • Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
    • Iaffaldano P, Lucisano G, Pozzilli C, et al., Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain 2015; 138 (pt 11): 3275-3286.
    • (2015) Brain , vol.138 , pp. 3275-3286
    • Iaffaldano, P.1    Lucisano, G.2    Pozzilli, C.3
  • 13
    • 84899004764 scopus 로고    scopus 로고
    • Switching from natalizumab to fingolimod in multiple sclerosis: A French prospective study
    • Cohen M, Maillart E, Tourbah A, et al., Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014; 71: 436-441.
    • (2014) JAMA Neurol , vol.71 , pp. 436-441
    • Cohen, M.1    Maillart, E.2    Tourbah, A.3
  • 14
    • 84936999643 scopus 로고    scopus 로고
    • Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
    • Kappos L, Radue EW, Comi G, et al., Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology 2015; 85: 29-39.
    • (2015) Neurology , vol.85 , pp. 29-39
    • Kappos, L.1    Radue, E.W.2    Comi, G.3
  • 15
    • 39049142995 scopus 로고    scopus 로고
    • B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
    • Hauser SL, Waubant E, Arnold DL, et al., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
    • (2008) N Engl J Med , vol.358 , pp. 676-688
    • Hauser, S.L.1    Waubant, E.2    Arnold, D.L.3
  • 17
    • 84897025098 scopus 로고    scopus 로고
    • A changing treatment landscape for multiple sclerosis: Challenges and opportunities
    • Piehl F,. A changing treatment landscape for multiple sclerosis: challenges and opportunities. J Intern Med 2014; 275: 364-381.
    • (2014) J Intern Med , vol.275 , pp. 364-381
    • Piehl, F.1
  • 18
    • 84929468055 scopus 로고    scopus 로고
    • Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
    • Dong-Si T, Richman S, Wattjes MP, et al., Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014; 1: 755-764.
    • (2014) Ann Clin Transl Neurol , vol.1 , pp. 755-764
    • Dong-Si, T.1    Richman, S.2    Wattjes, M.P.3
  • 19
    • 41849116363 scopus 로고    scopus 로고
    • Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase i trial
    • Bar-Or A, Calabresi PA, Arnold D, et al., Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395-400.
    • (2008) Ann Neurol , vol.63 , pp. 395-400
    • Bar-Or, A.1    Calabresi, P.A.2    Arnold, D.3
  • 20
    • 77953335494 scopus 로고    scopus 로고
    • Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
    • Naismith RT, Piccio L, Lyons JA, et al., Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010; 74: 1860-1867.
    • (2010) Neurology , vol.74 , pp. 1860-1867
    • Naismith, R.T.1    Piccio, L.2    Lyons, J.A.3
  • 21
    • 84857856422 scopus 로고    scopus 로고
    • Maximally tolerated versus minimally effective dose: The case of rituximab in multiple sclerosis
    • Nielsen AS, Miravalle A, Langer-Gould A, et al., Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler 2012; 18: 377-378.
    • (2012) Mult Scler , vol.18 , pp. 377-378
    • Nielsen, A.S.1    Miravalle, A.2    Langer-Gould, A.3
  • 22
    • 70449418132 scopus 로고    scopus 로고
    • Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
    • Hawker K, O'Connor P, Freedman MS, et al., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
    • (2009) Ann Neurol , vol.66 , pp. 460-471
    • Hawker, K.1    O'Connor, P.2    Freedman, M.S.3
  • 23
    • 76149093586 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    • Kappos L, Radue EW, O'Connor P, et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
    • (2010) N Engl J Med , vol.362 , pp. 387-401
    • Kappos, L.1    Radue, E.W.2    O'Connor, P.3
  • 24
    • 84901197534 scopus 로고    scopus 로고
    • Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial
    • Calabresi PA, Radue EW, Goodin D, et al., Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-556.
    • (2014) Lancet Neurol , vol.13 , pp. 545-556
    • Calabresi, P.A.1    Radue, E.W.2    Goodin, D.3
  • 25
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • Cohen JA, Barkhof F, Comi G, et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
    • (2010) N Engl J Med , vol.362 , pp. 402-415
    • Cohen, J.A.1    Barkhof, F.2    Comi, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.